Analyst Reco. Bristol-Myers Squibb Company Buenos Aires S.E.

Equities

BMY

ARDEUT112877

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 25/06/2024 am IST			5-day change	1st Jan Change
18,504 ^ARS	-0.15%		+7.46%	+12.44%

11:19pm	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
06:28pm	Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	01/05	MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	30/04
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	29/04	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	29/04	MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	26/04	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	26/04	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	26/04	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	26/04	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	26/04	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	26/04	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	26/04	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	25/04	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	25/04	MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	22/04	MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	18/04	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	15/04	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	15/04	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	12/04	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	09/04	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	11/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST